Ignite Creation Date:
2025-12-25 @ 1:39 AM
Ignite Modification Date:
2026-01-06 @ 10:25 PM
Study NCT ID:
NCT03397394
Status:
TERMINATED
Last Update Posted:
2023-06-09
First Post:
2017-12-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sponsor:
pharmaand GmbH
Organization:
Study Overview
Official Title:
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
TERMINATED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATLAS
Brief Summary:
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2017-004166-10 | EUDRACT_NUMBER | None | View |